Resmed continues its push to integrate healthcare analytics and cloud-based software into its respiratory management devices with its proposed $800m acquisition of Brightree, a developer of cloud-based software for improving clinical and business performance for providers of post-acute care. The move expands ResMed's offerings to its core HME/DME sleep customers and opens doors in new market segments, including home health and hospital channels, where there is a high prevalence of sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases.
ResMed Inc. is further strengthening its healthcare informatics offering with a proposed $800m acquisition of Brightree LLC, a developer of cloud-based software for improving clinical and business performance for providers of post-acute care.
Brightree’s software – designed to manage billing, inventory and resupply, documentation, revenue cycle, patient collections and physician referrals, among other things – is targeted at four segments of the post-acute...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
